Keyphrases
Acute Leukemia
5%
Acute Lymphoblastic Leukemia
100%
Acute Lymphoblastic Leukemia Cells
15%
Acute Myeloid Leukemia
25%
B-cell Acute Lymphoblastic Leukemia (B-ALL)
7%
BCP-ALL
7%
Bone Marrow
6%
Bone Mineral Density
6%
Chemotherapy
10%
Childhood Acute Lymphoblastic Leukemia
61%
Childhood Cancer
7%
Childhood Cancer Survivors
7%
Childhood Leukemia
13%
Children with Cancer
5%
Clinical Outcomes
7%
Daunorubicin
13%
Drug Resistance
20%
Drug Resistance Profiles
5%
Dutch
13%
Event-free Survival
10%
Glucocorticoid Resistance
10%
High Risk
5%
Immunophenotyping
7%
In Vitro Resistance
16%
Infant Acute Lymphoblastic Leukemia
17%
L-asparaginase
29%
Leukemia
21%
Leukemia Patients
22%
Leukemic Cells
8%
Long-term Survivors
6%
Methotrexate
16%
MicroRNA
6%
Minimal Residual Disease
12%
Mixed-phenotype Acute Leukemia
10%
MTT Assay
8%
Multidrug Resistance Protein 1 (MDR1)
6%
Netherlands
8%
Neuroblastoma
7%
Newly Diagnosed
5%
Oncology
7%
Pediatric
23%
Pediatric Acute Lymphoblastic Leukemia
28%
Pediatric Leukemia
16%
Pediatric Patients
6%
Prednisolone
21%
Prednisone
6%
Prognostic Significance
6%
Survivors
10%
T-cell Acute Lymphoblastic Leukemia (T-ALL)
24%
Working Diagnosis
7%
Medicine and Dentistry
Acute Leukemia
6%
Acute Lymphoblastic Leukemia
87%
Acute Myeloid Leukemia
20%
Adolescence
7%
Asparaginase
5%
B Cell
9%
Chemotherapy
11%
Childhood Cancer
17%
Disease
7%
Drug Resistance
14%
Event Free Survival
7%
Ganglioneuroblastoma
8%
Gene Expression
5%
In Vitro
16%
Leukemia
18%
Leukemia Cell
7%
Malignant Neoplasm
14%
Minimal Residual Disease
9%
Neoplasm
7%
Oncology
6%
Overall Survival
7%
Pediatric Acute Myeloid Leukemia
11%
Pediatrics
30%
Precursor
8%
Prednisolone
8%
Prognostic Factor
7%
Vincristine
6%
Wilms' Tumor
6%